10.1371/journal.pone.0098557.g002
Justin P. Williams
Justin
P. Williams
Inki Kim
Inki
Kim
Emma Ito
Emma
Ito
Wei Shi
Wei
Shi
Shijun Yue
Shijun
Yue
Lillian L. Siu
Lillian
L. Siu
John Waldron
John
Waldron
Brian O'Sullivan
Brian
O'Sullivan
Kenneth W. Yip
Kenneth
W. Yip
Fei-Fei Liu
Fei-Fei
Liu
Dacomitinib demonstrated <i>in vitro</i> efficacy in EGFR over-expressing SCCHN cell lines.
Public Library of Science
2014
physiology
Endocrine physiology
Growth factors
Epidermal growth factor
oncology
Cancers and neoplasms
carcinomas
Squamous cell carcinomas
Head and neck squamous cell carcinoma
Head and neck tumors
Cancer treatment
Radiation therapy
demonstrated
efficacy
egfr
over-expressing
scchn
2014-05-22 03:33:55
Figure
https://plos.figshare.com/articles/figure/_Dacomitinib_demonstrated_in_vitro_efficacy_in_EGFR_over_expressing_SCCHN_cell_lines_/1034699
<p>(A to D) Growth inhibition of three SCCHN and the NOE cell lines, treated with Dacomitinib, with or without IR. (B) FaDu; (C) UT-SCC-8; (D) UT-SCC-42a; and (E) NOE cells were treated with Dacomitinib (0, 10, 25, 50, 100, or 250 nM) alone, or in combination with IR (0, 2, or 4 Gy). MTS assays were conducted 72 hours post-treatment. The graphs represent data from 3 independent experiments, with the mean ± SEM reported. *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA. No statistically significant difference between curves for Figure 2A-D; two-way ANOVA. Combination of Dacomitinib plus RT did not result in a synergistic interaction for any of the dosing regimens in all three SCCHN cell lines (Chou-Talalay Method).</p>